Anaplastic Large Cell Lymphoma: Crizotinib Approved for Younger Patients

Crizotinib (Xalkori®, Pfizer) is now FDA approved for the treatment of pediatric patients age one year and older and young adult patients with relapsed/refractory systemic ALK-positive anaplastic large cell lymphoma (ALCL). The approval was based on Study ADVL0912 (NCT00939770), a single-arm phase 1/2 trial. "Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as ALCL, inflammatory myofibroblastic tumors, non-small cell lung cancer (NSCLC), and neurob...

Continue reading

Delaying Radical Prostatectomy: Risky or Safe?

Patients can safely delay a radical prostatectomy for up to 180 days after diagnosis of high-risk prostate cancer, according to results of a study now published in JAMA Network Open. Using the US National Cancer Database (NCDB), the researchers collected data on 32,184 patients with clinically localized high-risk prostate adenocarcinoma who were diagnosed between the years 2006 and 2016 and who underwent a radical prostatectomy. Patients were categorized into 5 groups according to surgical delay...

Continue reading

Pembrolizumab After Locally Ablative Therapy in NSCLC: Joshua Bauml, MD

Locally ablative therapy, which consists of surgery, radiation, and other definitive treatments at all sites of metastasis, has shown efficacy in oligometastatic non-small cell lung cancer (NSCLC). Given that immunotherapy has also shown efficacy in NSCLC, Joshua Bauml, MD, and colleagues at the University of Pennsylvania's Perelman School of Medicine investigated the combination of locally ablative therapy with pembrolizumab (Keytruda®, Merck). The investigators found that adding pembrolizumab ...

Continue reading

NSCLC: Pembrolizumab Following Locally Ablative Therapy

​A phase 2 clinical trial reports that the addition of pembrolizumab (Keytruda®, Merck) following locally ablative therapy for oligometastatic non-small cell lung cancer (NSCLC) improves median progression-free survival compared with historical data. About 7% of patients with NSCLC have oligometastatic disease, a state of limited systemic metastasis that could be cured by means of locally ablative therapy. A treatment consisting of surgery and radiation at all sites of metastasis, locally ablati...

Continue reading

Androgen Deprivation for Prostate Cancer Linked to Dementia

​Androgen deprivation therapy (ADT) is associated with diagnoses of dementia in men with prostate cancer, according to a new study.  Androgen deprivation therapy, either alone or in combination with other forms of therapy, is an effective treatment for high-risk prostate cancer in all stages from localized to metastatic disease. However, it has its drawbacks, including potential long-term effects on bone, sexual, and cardiovascular health. According to researchers from the Perelman Sch...

Continue reading

Avoiding Narcotics in Post-Surgery Cancer Pain Management

​Opioid addiction, which is currently so widespread that it amounts to a national crisis, often starts with the legitimate use of prescription pain medication after surgery or as a result of another medical condition. For this reason, it is essential to develop non-narcotic strategies to handle pain. A team of researchers in the Perelman School of Medicine at the University of Pennsylvania did just that, designing a program that successfully managed post-surgery pain for patients with urolo...

Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2022 Oncology Data Advisor. All rights reserved.